Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089904 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04089904 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 3 participants.
The verdict
NCT04089904, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.
Interventions
- DRUG Pembrolizumab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-10-11 |
| Est. Completion | 2023-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089904
The ClinicalTrials.gov registry entry for NCT04089904 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab Injection is the first listed.
NCT04089904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04089904 about?
NCT04089904 is a clinical study titled "Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma". To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.
What is the current status of trial NCT04089904?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-10-11. Estimated completion is 2023-03-11.
What interventions are being tested in trial NCT04089904?
The interventions under investigation include: Pembrolizumab Injection (DRUG).
Who is sponsoring clinical trial NCT04089904?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.